Genome-wide antibiotic-CRISPRi profiling identifies LiaR activation as a strategy to resensitize fluoroquinolone-resistant Streptococcus pneumoniae
Bevika Sewgoolam, Kin Ki Jim, Vincent de Bakker, Florian Patrick Bock, Paddy S. Gibson, Jan‐Willem Veening
The paper identifies LiaR activation as a strategy to resensitize fluoroquinolone-resistant Streptococcus pneumoniae using CRISPRi-seq and antibiotic combination therapy.
Nature Communications · Jul 14, 2025Peer-reviewedMicrobiology